Vilella, A.; Ruozi, B.; Belletti, D.; Pederzoli, F.; Galliani, M.; Semeghini, V.; Forni, F.; Zoli, M.; Vandelli, M.A.; Tosi, G.
Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles. Pharmaceutics 2015, 7, 74-89.
https://doi.org/10.3390/pharmaceutics7020074
AMA Style
Vilella A, Ruozi B, Belletti D, Pederzoli F, Galliani M, Semeghini V, Forni F, Zoli M, Vandelli MA, Tosi G.
Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles. Pharmaceutics. 2015; 7(2):74-89.
https://doi.org/10.3390/pharmaceutics7020074
Chicago/Turabian Style
Vilella, Antonietta, Barbara Ruozi, Daniela Belletti, Francesca Pederzoli, Marianna Galliani, Valentina Semeghini, Flavio Forni, Michele Zoli, Maria Angela Vandelli, and Giovanni Tosi.
2015. "Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles" Pharmaceutics 7, no. 2: 74-89.
https://doi.org/10.3390/pharmaceutics7020074
APA Style
Vilella, A., Ruozi, B., Belletti, D., Pederzoli, F., Galliani, M., Semeghini, V., Forni, F., Zoli, M., Vandelli, M. A., & Tosi, G.
(2015). Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles. Pharmaceutics, 7(2), 74-89.
https://doi.org/10.3390/pharmaceutics7020074